FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

Yiling

Drug and asset intelligence for Yiling with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 2
Stage: Development stage unavailable

Recent signals(2)

RegulatoryJuly 1, 2026

FDA Accepts Supplement for Aciclovir ANDA210401 by Yiling

The FDA has accepted a supplemental application for Aciclovir under ANDA210401 submitted by Yiling.

StrategyJuly 1, 2026

FDA Grants Approval for Aciclovir ANDA212173 by YILING

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 212173 for acyclovir submitted by YILING.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

— YILING

Monitor market entry timelines and pricing strategies from YILING and competitors.

July 1, 2026 · N/A

Topline Data

— Yiling

Monitor the progress of the review and any subsequent approvals or market entries by competitors.

July 1, 2026 · N/A

Indications

Infectious Disease →

Therapeutic areas

Antiviral →

Infectious Disease →

Infectious Disease · Antiviral →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.